Literature DB >> 35868344

Gut-brain communication in COVID-19: molecular mechanisms, mediators, biomarkers, and therapeutics.

Tameena Wais1, Mehde Hasan1, Vikrant Rai1, Devendra K Agrawal1.   

Abstract

INTRODUCTION: Infection with COVID-19 results in acute respiratory symptoms followed by long COVID multi-organ effects presenting with neurological, cardiovascular, musculoskeletal, and gastrointestinal (GI) manifestations. Temporal relationship between gastrointestinal and neurological symptoms is unclear but warranted for exploring better clinical care for COVID-19 patients. AREAS COVERED: We critically reviewed the temporal relationship between gut-brain axis after SARS-CoV-2 infection and the molecular mechanisms involved in neuroinvasion following GI infection. Mediators are identified that could serve as biomarkers and therapeutic targets in SARS-CoV-2. We discussed the potential therapeutic approaches to mitigate the effects of GI infection with SARS-CoV-2. EXPERT OPINION: Altered gut microbiota cause increased expression of various mediators, including zonulin causing disruption of tight junction. This stimulates enteric nervous system and signals to CNS precipitating neurological sequalae. Published reports suggest potential role of cytokines, immune cells, B(0)AT1 (SLC6A19), ACE2, TMRSS2, TMPRSS4, IFN-γ, IL-17A, zonulin, and altered gut microbiome in gut-brain axis and associated neurological sequalae. Targeting these mediators and gut microbiome to improve immunity will be of therapeutic significance. In-depth research and well-designed large-scale population-based clinical trials with multidisciplinary and collaborative approaches are warranted. Investigating the temporal relationship between organs involved in long-term sequalae is critical due to evolving variants of SARS-CoV-2.

Entities:  

Keywords:  ACE-2 receptor; COVID-19; Gut-brain axis; enteric nervous system; gastrointestinal tract

Mesh:

Substances:

Year:  2022        PMID: 35868344      PMCID: PMC9388545          DOI: 10.1080/1744666X.2022.2105697

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   5.124


  110 in total

1.  Rufinamide, an antiepileptic drug, improves cognition and increases neurogenesis in the aged gerbil hippocampal dentate gyrus via increasing expressions of IGF-1, IGF-1R and p-CREB.

Authors:  Bai Hui Chen; Ji Hyeon Ahn; Joon Ha Park; Minah Song; Hyunjung Kim; Tae-Kyeong Lee; Jae Chul Lee; Young-Myeong Kim; In Koo Hwang; Dae Won Kim; Choong-Hyun Lee; Bing Chun Yan; Il Jun Kang; Moo-Ho Won
Journal:  Chem Biol Interact       Date:  2018-03-14       Impact factor: 5.192

2.  The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses.

Authors:  Valérie Gaboriau-Routhiau; Sabine Rakotobe; Emelyne Lécuyer; Imke Mulder; Annaïg Lan; Chantal Bridonneau; Violaine Rochet; Annamaria Pisi; Marianne De Paepe; Giovanni Brandi; Gérard Eberl; Johannes Snel; Denise Kelly; Nadine Cerf-Bensussan
Journal:  Immunity       Date:  2009-10-16       Impact factor: 31.745

Review 3.  ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy.

Authors:  Colleen T Cole-Jeffrey; Meng Liu; Michael J Katovich; Mohan K Raizada; Vinayak Shenoy
Journal:  J Cardiovasc Pharmacol       Date:  2015-12       Impact factor: 3.105

4.  Insulin-Like Growth Factor 1 Regulates Acute Inflammatory Lung Injury Mediated by Influenza Virus Infection.

Authors:  Guiping Li; Lijuan Zhou; Can Zhang; Yun Shi; Derong Dong; Miao Bai; Rong Wang; Chuanfu Zhang
Journal:  Front Microbiol       Date:  2019-11-26       Impact factor: 5.640

5.  Faecal calprotectin indicates intestinal inflammation in COVID-19.

Authors:  Maria Effenberger; Felix Grabherr; Lisa Mayr; Julian Schwaerzler; Manfred Nairz; Markus Seifert; Richard Hilbe; Stefanie Seiwald; Sabine Scholl-Buergi; Gernot Fritsche; Rosa Bellmann-Weiler; Günter Weiss; Thomas Müller; Timon Erik Adolph; Herbert Tilg
Journal:  Gut       Date:  2020-04-20       Impact factor: 23.059

Review 6.  COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract.

Authors:  Michail Galanopoulos; Filippos Gkeros; Aris Doukatas; Grigorios Karianakis; Christos Pontas; Nikolaos Tsoukalas; Nikos Viazis; Christos Liatsos; Gerassimos J Mantzaris
Journal:  World J Gastroenterol       Date:  2020-08-21       Impact factor: 5.742

7.  Molecular chronicles of cytokine burst in patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseases.

Authors:  Finosh G Thankam; Devendra K Agrawal
Journal:  J Thorac Cardiovasc Surg       Date:  2020-06-06       Impact factor: 5.209

Review 8.  Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis.

Authors:  Lavienraj Premraj; Nivedha V Kannapadi; Jack Briggs; Stella M Seal; Denise Battaglini; Jonathon Fanning; Jacky Suen; Chiara Robba; John Fraser; Sung-Min Cho
Journal:  J Neurol Sci       Date:  2022-01-29       Impact factor: 3.181

9.  Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial.

Authors:  Pedro Gutiérrez-Castrellón; Tania Gandara-Martí; Ana T Abreu Y Abreu; Cesar D Nieto-Rufino; Eduardo López-Orduña; Irma Jiménez-Escobar; Carlos Jiménez-Gutiérrez; Gabriel López-Velazquez; Jordi Espadaler-Mazo
Journal:  Gut Microbes       Date:  2022 Jan-Dec

10.  The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.

Authors:  Kun Li; David K Meyerholz; Jennifer A Bartlett; Paul B McCray
Journal:  mBio       Date:  2021-08-03       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.